Concomitant treatment of rheumatoid arthritis with anti-TNF-α antibodies and methotrexate
US8298537B2 · kind B2 · utility
3Cited by
27References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 13, 2012 |
| Grant date | Oct 30, 2012 |
| Priority date | — |
| Expiry date | Jan 13, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.